Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Structure Therapeutics GPCR, a clinical-stage company, is expected to report second-quarter 2024 results soon. Structure Therapeutics’ lead product candidate is GSBR-1290, a highly selective oral ...

Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...

Structure Therapeutics Inc. Sponsored ADR (GPCR) closed the last trading session at $40.50, gaining 17.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term ...